Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Clinical presentation and management of patients with mucopolysaccharidosis type II in Children's Hospital Zagreb (CROSBI ID 520569)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Barišić, Ingeborg ; Tokić, Višnja ; Petković, Giorgie ; Fumić, Ksenija Clinical presentation and management of patients with mucopolysaccharidosis type II in Children's Hospital Zagreb // 6th International Symposium on Lysosomal Storage Diseases - poster abstracts. Stockholm: TKT Europe AB, Rinkebyvagen 11B, SE-182 36 Danderyd, Sweden, 2006. str. 92-x

Podaci o odgovornosti

Barišić, Ingeborg ; Tokić, Višnja ; Petković, Giorgie ; Fumić, Ksenija

engleski

Clinical presentation and management of patients with mucopolysaccharidosis type II in Children's Hospital Zagreb

Mucopolysaccharidosis type II (MPS II) is a rare X-linked recessive disorder due to the deficiency of the lysosome enzyme iduronate sulfatase (IDS). This results in the lysosomal accumulation of dermatan and heparan sulfate causing progressive dysfunction of many tissues and organs. Aim: to present clinical phenotype, natural course and management of our patients with MPS II. Patients/Methods: During the last ten years we have diagnosed three patients with MPS II. The diagnosis was made based on clinical criteria, abnormal urinary glycosaminoglycan excretion, deficient serum and/or fibroblast IDS activity, and molecular testing. Results: All patients presented with the severe form of the disease. The delay between symptom onset and first visit to a physician was 21 months, 6 months, and 6 weeks and the gap between the first visit to diagnosis was 5 years, 3 years and 2.5 years respectively. Multidisciplinary approach in the management of MPS II patients was adopted, integrating all aspects of their care, but the results are so far limited. Conclusions: there is a significant gap between early symptoms and diagnosis of MPS II in Croatia. An increased awareness of MPS II among the medical communitiy should help to reduce the diagnostic delay in these patietns. This is particularly important having in view the prospect of enzyme replacement therapy for this disorder.

lysosomal storage disease; mucopolysaccharidosis II; clinical presentation; management

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

92-x.

2006.

objavljeno

Podaci o matičnoj publikaciji

6th International Symposium on Lysosomal Storage Diseases - poster abstracts

Stockholm: TKT Europe AB, Rinkebyvagen 11B, SE-182 36 Danderyd, Sweden

Podaci o skupu

6th International Symposium on Lysosomal Storage Diseases

poster

28.04.2006-29.04.2006

Stockholm, Švedska

Povezanost rada

Kliničke medicinske znanosti